Shareholders Reject Equity Incentive Plan Expansion, Limit Future Dilution

summarizeSummary

Alto Neuroscience shareholders rejected a proposal to expand the 2024 Equity Incentive Plan, limiting potential future dilution, while approving a smaller amendment to the Employee Stock Purchase Plan.

check_boxKey Events

• Equity Incentive Plan Expansion Rejected

  Stockholders did not approve the proposed amendment to the 2024 Equity Incentive Plan, which would have included pre-funded warrants in the calculation for automatic share reserve increases.

• Employee Stock Purchase Plan Amendment Approved

  Stockholders approved an amendment to the 2024 Employee Stock Purchase Plan to include pre-funded warrants in its 'evergreen' share reserve calculation.

• Directors Re-elected and Auditor Ratified

  Raymond Sanchez, M.D. and Gwill York were re-elected as Class II directors, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis

Shareholders voted against expanding the 2024 Equity Incentive Plan's share reserve to include pre-funded warrants in its 'evergreen' calculation. This decision limits potential future dilution for existing shareholders, especially following a recent $120 million private placement that included pre-funded warrants and a failed Phase 2 drug study. While an amendment to the Employee Stock Purchase Plan was approved, the rejection of the larger equity incentive plan amendment signals strong shareholder vigilance regarding equity issuance.